PE20171515A1 - Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer - Google Patents
Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancerInfo
- Publication number
- PE20171515A1 PE20171515A1 PE2017001485A PE2017001485A PE20171515A1 PE 20171515 A1 PE20171515 A1 PE 20171515A1 PE 2017001485 A PE2017001485 A PE 2017001485A PE 2017001485 A PE2017001485 A PE 2017001485A PE 20171515 A1 PE20171515 A1 PE 20171515A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- peptides
- seq
- new
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000037029 cross reaction Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134253P | 2015-03-17 | 2015-03-17 | |
| GB201504502A GB201504502D0 (en) | 2015-03-17 | 2015-03-17 | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171515A1 true PE20171515A1 (es) | 2017-10-20 |
Family
ID=53016273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001485A PE20171515A1 (es) | 2015-03-17 | 2016-03-17 | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10076560B2 (OSRAM) |
| EP (1) | EP3270952A1 (OSRAM) |
| JP (1) | JP6715856B2 (OSRAM) |
| KR (1) | KR102718168B1 (OSRAM) |
| CN (2) | CN113563456A (OSRAM) |
| AR (2) | AR121588A2 (OSRAM) |
| AU (4) | AU2016232140B2 (OSRAM) |
| BR (1) | BR112017019217A2 (OSRAM) |
| CA (1) | CA2979506A1 (OSRAM) |
| CR (3) | CR20210233A (OSRAM) |
| EA (1) | EA037783B1 (OSRAM) |
| GB (1) | GB201504502D0 (OSRAM) |
| MA (3) | MA46647A1 (OSRAM) |
| MX (1) | MX2017011857A (OSRAM) |
| PE (1) | PE20171515A1 (OSRAM) |
| SG (2) | SG10202001404VA (OSRAM) |
| TW (2) | TWI769586B (OSRAM) |
| UA (1) | UA123392C2 (OSRAM) |
| WO (1) | WO2016146751A1 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014110591A1 (en) | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| TWI755158B (zh) | 2015-03-17 | 2022-02-11 | 德商英麥提克生物技術股份有限公司 | 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合 |
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| CA3008641A1 (en) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| EP4371584A3 (en) * | 2016-12-21 | 2024-08-28 | Fred Hutchinson Cancer Center | Scaffolds to treat solid tumor cells and escape variants |
| MA49122A (fr) * | 2017-04-10 | 2021-03-24 | Immatics Biotechnologies Gmbh | Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse |
| ES3041991T3 (en) | 2017-05-25 | 2025-11-17 | Leidos Inc | Pd-1 and ctla-4 dual inhibitor peptides |
| LT3652215T (lt) | 2017-07-14 | 2021-05-25 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| US11464800B2 (en) * | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| AU2018410849B2 (en) | 2018-02-27 | 2025-02-27 | Leidos, Inc. | PD-1 peptide inhibitors |
| EP3765053A2 (en) * | 2018-03-16 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
| WO2019175380A2 (en) * | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| CA3141162A1 (en) | 2019-05-22 | 2020-11-26 | Leidos, Inc. | Lag3 binding peptides |
| PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| PH12021553042A1 (en) | 2019-06-06 | 2023-09-11 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| KR20230003560A (ko) * | 2020-04-29 | 2023-01-06 | 타이페이 메디컬 유니이버시티 | 대장암의 조기 발견, 치료 반응의 예측 및 예후 방법 |
| JP7560850B2 (ja) * | 2020-07-01 | 2024-10-03 | 学校法人関西医科大学 | 尿路系上皮腫瘍関連病変を検出するためのバイオマーカー |
| CA3189692A1 (en) | 2020-07-31 | 2022-02-03 | Leidos, Inc. | Lag3 binding peptides |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CA3198203A1 (en) | 2020-10-12 | 2022-04-21 | Leidos, Inc. | Immunomodulatory peptides |
| CN112557347B (zh) * | 2020-11-12 | 2023-10-24 | 渤海大学 | 一种黏液层中乳糜粒子迁移模型的制备及检测方法 |
| CN112462066B (zh) * | 2020-12-03 | 2023-05-19 | 中南大学湘雅医院 | Fam3c蛋白及其特异性抗体在制备检测鼻咽癌试剂盒中的应用、试剂盒及其应用 |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| CN112760383B (zh) * | 2021-03-02 | 2023-07-21 | 上海欧易生物医学科技有限公司 | 应用于肺腺癌细胞亚群的一组qRT-PCR内参基因及其应用 |
| CN114163510B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| KR102618065B1 (ko) * | 2021-12-10 | 2023-12-22 | 성균관대학교산학협력단 | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단 방법 |
| CN114214406A (zh) * | 2021-12-15 | 2022-03-22 | 天津医科大学总医院 | 一种用于评价肿瘤患者免疫治疗反应性和评估肿瘤预后的三联标志物及其应用 |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN119724622B (zh) * | 2024-11-25 | 2025-12-12 | 中国人民解放军总医院第五医学中心 | 一种评价ptt对胰腺癌治疗效果的方法、系统及设备 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610031A (en) * | 1993-10-27 | 1997-03-11 | The General Hospital Corporation | B1k chain of laminin and methods of use |
| US6316213B1 (en) * | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
| AU4158799A (en) * | 1998-06-06 | 1999-12-30 | Genostic Pharma Limited | Probes used for genetic filing |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| JP2004500059A (ja) * | 1999-12-10 | 2004-01-08 | エピミューン インコーポレイテッド | ペプチドおよび核酸組成物を使用する、癌胎児性抗原に対する細胞性免疫応答の誘導 |
| AU2273701A (en) * | 1999-12-13 | 2001-06-18 | Epimmune, Inc. | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| CN1469926A (zh) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
| WO2003010327A2 (en) * | 2001-02-21 | 2003-02-06 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| US20030021796A1 (en) * | 2001-05-04 | 2003-01-30 | Leszek Ignatowicz | Method of enhancing T cell immunity by selection of antigen specific T cells |
| JP2003321494A (ja) * | 2002-02-26 | 2003-11-11 | Daiichi Fine Chemical Co Ltd | プロｍｍｐ−７の活性化調節方法 |
| EP2070949B1 (en) * | 2002-06-10 | 2013-01-16 | Vaccinex, Inc. | C35 antibodies and their use in the treatment of cancer |
| JP2006516089A (ja) * | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| WO2004050858A2 (en) * | 2002-12-04 | 2004-06-17 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| DK2186896T3 (en) * | 2004-03-31 | 2015-12-21 | Int Inst Cancer Immunology Inc | Cancer antigen peptides derived from WT1 |
| ES2330013T3 (es) * | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
| GB0611116D0 (en) * | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
| HUE027057T2 (en) * | 2007-07-27 | 2016-08-29 | Immatics Biotechnologies Gmbh | New immunogenic epitope for immunotherapy |
| EP2127664A1 (en) * | 2008-02-15 | 2009-12-02 | Max-Delbrück-Centrum | Change of the load state of MHC molecules by dipeptides |
| WO2009123349A1 (ja) * | 2008-03-31 | 2009-10-08 | オリエンタル酵母工業株式会社 | 多能性幹細胞を増殖させる方法 |
| HUE024541T2 (hu) * | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek |
| WO2010047938A2 (en) * | 2008-10-21 | 2010-04-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Mmp activation peptide detection in biological samples |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| CA2840472A1 (en) * | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| AU2012301664A1 (en) * | 2011-08-31 | 2014-02-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of cancer |
| EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US20140065620A1 (en) * | 2011-12-29 | 2014-03-06 | Mayo Foundation For Medical Education And Research | Nucleic acids for detecting breast cancer |
| TWI636065B (zh) * | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| CN104163862B (zh) * | 2013-12-04 | 2017-02-08 | 魏敏杰 | 与人mhc‑i类分子结合的grp78多肽表位 |
| CN104306976A (zh) * | 2014-04-26 | 2015-01-28 | 深圳市康尔诺生物技术有限公司 | 一种高效的肿瘤个体化免疫治疗方法及其应用 |
-
2015
- 2015-03-17 GB GB201504502A patent/GB201504502D0/en not_active Ceased
-
2016
- 2016-03-17 TW TW109140068A patent/TWI769586B/zh active
- 2016-03-17 SG SG10202001404VA patent/SG10202001404VA/en unknown
- 2016-03-17 PE PE2017001485A patent/PE20171515A1/es unknown
- 2016-03-17 CA CA2979506A patent/CA2979506A1/en active Pending
- 2016-03-17 MX MX2017011857A patent/MX2017011857A/es unknown
- 2016-03-17 AU AU2016232140A patent/AU2016232140B2/en not_active Ceased
- 2016-03-17 CN CN202110838669.8A patent/CN113563456A/zh active Pending
- 2016-03-17 CN CN201680015234.0A patent/CN107428810B/zh active Active
- 2016-03-17 MA MA46647A patent/MA46647A1/fr unknown
- 2016-03-17 SG SG11201706155XA patent/SG11201706155XA/en unknown
- 2016-03-17 CR CR20210233A patent/CR20210233A/es unknown
- 2016-03-17 EP EP16710223.5A patent/EP3270952A1/en active Pending
- 2016-03-17 BR BR112017019217-9A patent/BR112017019217A2/pt not_active Application Discontinuation
- 2016-03-17 WO PCT/EP2016/055817 patent/WO2016146751A1/en not_active Ceased
- 2016-03-17 CR CR20210234A patent/CR20210234A/es unknown
- 2016-03-17 UA UAA201707771A patent/UA123392C2/uk unknown
- 2016-03-17 TW TW105108310A patent/TWI726872B/zh active
- 2016-03-17 JP JP2017547530A patent/JP6715856B2/ja active Active
- 2016-03-17 EA EA201791853A patent/EA037783B1/ru unknown
- 2016-03-17 KR KR1020177025935A patent/KR102718168B1/ko active Active
- 2016-03-17 US US15/073,528 patent/US10076560B2/en active Active
- 2016-03-17 CR CR20170419A patent/CR20170419A/es unknown
- 2016-03-17 MA MA40713A patent/MA40713A1/fr unknown
- 2016-03-17 MA MA46648A patent/MA46648B2/fr unknown
-
2018
- 2018-01-12 US US15/869,471 patent/US10357551B2/en active Active
-
2020
- 2020-08-18 AU AU2020220070A patent/AU2020220070B2/en not_active Ceased
- 2020-08-18 AU AU2020220073A patent/AU2020220073B2/en not_active Ceased
- 2020-08-18 AU AU2020220072A patent/AU2020220072B2/en not_active Ceased
-
2021
- 2021-02-24 AR ARP210100473A patent/AR121588A2/es unknown
- 2021-02-24 AR ARP210100472A patent/AR121587A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171515A1 (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer | |
| PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| CL2018000124A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer | |
| PE20180487A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cancer | |
| PE20181316A1 (es) | Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer | |
| PE20170940A1 (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer | |
| PE20181517A1 (es) | Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer | |
| PE20180253A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer | |
| PE20191248A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| PE20171442A1 (es) | Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
| PE20190477A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
| PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
| PE20210376A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
| PE20190335A1 (es) | Receptores de celulas t | |
| PE20171765A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon amicrocitico y otros tipos de cancer | |
| BR112017007202A2 (pt) | receptores de célula t | |
| PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
| CL2021001794A1 (es) | Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227) | |
| MX2024002398A (es) | Proteinas de fusion gdf15 y usos de estas. | |
| BR112018070600A2 (pt) | receptores de células t | |
| PE20191711A1 (es) | Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer | |
| BR112018070625A2 (pt) | receptores de células t | |
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| PE20181490A1 (es) | Tratamientos contra el cancer de utero |